Publications of Y. Genzel

Schulze-Horsel, J.; Bock, A.; Genzel, Y.; Reichl, U.: Mammalian cell culture for influenza vaccine production: physiology during cell growth and virus propagation phase. GVC/DECHEMA-Jahrestagungen 2006 mit 24. DECHEMA-Jahrestagung der Biotechnologen, Wiesbaden, Germany (2006)

Genzel, Y.; Schulze-Horsel, J.; Möhler, L.; Sidorenko, Y.; Reichl, U.: Influenza Vaccines: Challenges in Mammalian Cell Culture Technology. 19th ESACT Meeting, Harrogate, UK (2005)

Genzel, Y.; König, S.; Reichl, U.: Amino acid analysis in mammalian cell culture based virus vaccine production processes. IICS : 17th annual International Ion Chromatography Symposium, Trier, Germany (2004)

Daumal, C.; Jacobtorweihe, L.; Behrendt, I.; Ermert, D.; Semmrich, M.; Genzel, Y.; Reichl, U.: Optimizing the Production of Oncolytic Herpes Simplex-1 Virus in Suspension HEK293 Cells. 5^th ESACT Frontiers Retreat, Ljubljana (Slovenia) (2025)

Dogra, T.; Pelz, L.; Rüdiger, D.; Hein, M.; Baelkner, M.; Boehme, J.D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y. et al.; Reichl, U.: Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 9^th European Congress of Virology (ECV), Cavtat/Dubrovnik (Croatia) (2025)

Jacobtorweihe, L.; Braatz, F.; Brice, M.; Léon, A.; Genzel, Y.; Reichl, U.: Intensification of oncolytic Newcastle disease virus production using EB66 duck cells in perfusion mode. 5^th ESACT Frontiers Retreat, Ljubljana (Slovenia) (2025)

Jacobtorweihe, L.; Braatz, F.; Madeline, B.; Léon, A.; Genzel, Y.; Reichl, U.: Production of Oncolytic Newcastle Disease Virus in EB66 cells: Characterization of Parameters for Process Intensification. Cell Culture Engineering (CCE) XIX, Tucson Arizona (USA) (2025)

Küchler, J.; Opitz, P.; Jordan, I.; Genzel, Y.; Benndorf, D.; Reichl, U.: Quantification of intracellular influenza A virus proteins shows changes in dynamics related to host cell line and virus seed. 9^th European Congress of Virology (ECV), Cavtat/Dubrovnik (Croatia) (2025)

Dogra, T.; Pelz, L.; Rüdiger, D.; Hein, M. D.; Böhme, J.; Bälkner, M.; Kershaw, O.; Marichal-Gallardo, P.; Gruber, A.; Genzel, Y. et al.; Bruder, D.; Kupke, S. Y.; Reichl, U.: Genetically engineered defective interfering particles for antiviral treatment and vaccination. 28th ESACT Meeting, Edingburgh (Scotland) (2024)

Göbel, S.; Kazemi, O.; Jordan, I.; Dallmeier, K.; Reichl, U.; Genzel, Y.: Multifactorial highthroughput process screening for a yellow-fever virus vectored Zika vaccine candidate. Vaccine Technology IX, Los Cabos (Mexico) (2024)

Göbel, S.; Pelz, L.; Silva, C.; Brühlmann, B.; Hill, C.; Altomonte, J.; Kamen, A.; Reichl, U.; Genzel, Y.: Intensified production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration. 28th ESACT Meeting, Edingburgh (Scotland) (2024)

Jacobtorweihe, L.; Göbel, S.; Wolschek, M.; Altomonte, J.; Reichl, U.; Genzel, Y.: HCD Perfusion of CCX.E10 Quail Cells for Production of Vesicular Stomatitis Virus based oncolytic Vaccine. Vaccine Technology IX, Los Cabos (Mexico) (2024)

Jacobtorweihe, L.; Göbel, S.; Wolschek, M.; Altomonte, J.; Reichl, U.; Genzel, Y.: Production of Oncolytic rVSV-NDV in CCX.E10 Quail Cells by HCD Perfusion Culture. Himmelfahrtstagung on Bioprocess Engineering 2024, Regensburg (Germany) (2024)

Jacobtorweihe, L.; Madeline, B.; Léon, A.; Genzel, Y.; Reichl, U.: Production of Oncolytic Newcastle Disease Virus in EB66 cells. 28th ESACT Meeting, Edingburgh (Scotland) (2024)

Küchler, J.; Opitz, P.; Jordan, I.; Genzel, Y.; Benndorf, D.; Reichl, U.: Quantification of intracellular influenza A virus proteins shows changes in dynamics related to host cell line and virus seed. 28th ESACT Meeting , Edingburgh (Scotland) (2024)

Küchler, J.; Opitz, P.; Jordan, I.; Genzel, Y.; Benndorf, D.; Reichl, U.: Quantification of intracellular influenza A virus proteins shows changes in dynamics related to host cell line and virus seed. Himmelfahrtstagung on Bioprocess Engineering 2024, Regensburg (Germany) (2024)

Zinnecker, T. M.; Thiele, K.; Schmidberger, T.; Reichl, U.; Genzel, Y.: Influenza A Virus Production following Quality by Design Principles. Vaccine Technology IX, Los Cabos (Mexico) (2024)

Zinnecker, T. M.; Thiele, K.; Schmidberger, T.; Reichl, U.; Genzel, Y.: Implementation of Quality by Design Principles for Influenza A Virus Production. 28th ESACT Meeting, Edingburgh (Scotland) (2024)

Dogra, T.; Pelz, L.; Rüdiger, D.; Hein, M. D.; Baelkner, M.; Julia D. Boehme, J. D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y. et al.; Reichl, U.: Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 32^nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)

Dogra, T.; Pelz, L.; Rüdiger, D.; Hein, M. D.; Baelkner, M.; Julia D. Boehme, J. D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y. et al.; Reichl, U.: Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 8^th European Congress of Virology, Gdańsk (Poland) (2023)